Study Group: Multiple Myeloma Physicians
Council Members in this Study Group: 211
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Robert Boorstein
Associate Professor, Pathology
NEW YORK UNIVERSITY (INC)
Robert Boorstein, MD, PhD, is an Associate Professor in the Department of Pathology at New York University School of Medicine, where he directs clinical pathology training. Previously, Dr. Boorstein was the Director of Pathology at Bellevue Hospital and...
Donald FlemingDivision Head of Hematology and Oncology
DAVIS HEALTH SYSTEM INCDonald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed...
- Eric Jacobsen
Instructor in Medicine
DANA-FARBER CANCER INSTITUTE, INC.Eric Jacobsen, MD, is Medical Oncologist and Hematologist in the Hematology and Oncology Department at the Dana-Farber Cancer Institute in Boston, MA. Dr. Jacobsen is a member of the lymphoma and bone marrow transplant divisions at Dana-Farber Cancer...
- William Matsui
Associate Professor
Johns Hopkins University - CCWilliam Matsui, MD, is an Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center and the Johns Hopkins School of Medicine in Maryland, since July 2008. Dr. Matsui specializes in clinical and laboratory examination of hematological...
Taral PatelOncologist
MID-OHIO ONCOLOGY & HEMOTOLOGY INCTaral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer,...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
November 14, 2009
US FDA accepts ChemGenex's Omapro NDA filing to treat CML, grants priority review status | www.pharmabiz.com
Patients with CML have a good prognosis when treated with TKI's An exception is the ones that develope a particular mutation known as T315IOnly SCT seems to be effective in this group of patients and maybe too morbid of therapy for many patients
-
What is potential future for Sequenom in prenatal testing.
November 9, 2009
So Where Does Sequenom’s Prenatal Play Currently Stand? | www.genomeweb.com
The historic but minimally supported enthusiasm for the Sequenom prenatal test has previously been reported in this space previously. Even in the absence of data retractions, leading to termination of much of senior management, problems in the rollout of the product should have been anticipated.Remarkably, this article asserts that industry insiders remain optimistic about the development of a successful diagnostic product.
-
Potential impact of large clinical trial on Liquid based cytology market
November 5, 2009
Alternative to Pap Test Does Not Appear to Be Better for Detecting Cervical Cancer | www.medcompare.com
The data confirms what has long been known. There has never been definitive evidence for a benefit for Liquid based cytology screening compared with conventional screening, especially when sample collection is standardized and the laboratory meets reasonable standards.Objectively, liquid based cytology has essentially replaced conventional Pat testing in this country, and it is unlikely that there is evidence that would reverse this. However, it is possible such studies will put downward pricing pressures on reimbursments, both in amounts and frequencies.
-
Triple negative Breast Cancer Strategies
October 14, 2009
MediGene completes patient recruitment into EndoTAGTM-1 phase II breast cancer trial | www.pharmabiz.com
Triple negative Breast cancer has been a phenotype with little hope up until recentlyWhile advances in hormonal therapy and Her2 blocking agents has revolutionized ER/PR + and Her 2 positive breast cancer therapy, triple negative breast cancer pulls down the outcomes, with similar responses as for non small cell lung cancer
-
Farletuzumab (F) helps the ovarian cancer patients that do well, do well?
September 25, 2009
Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects | www.pipelinereview.com
F recently demonstrated a great majority of platinum sensitive patients respond when given in combination with a platinum based regimen in recurrent ovarian caPlatinum sensitive patients typically do well with platinum based intervention, but it's the platinum resistant ( denovo or delayed) that we have a problem with
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Academic Institution*
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Division Head
- Physician - Director
- Director
- Partner
- Professor
Related Study Groups
GLG Live Meetings with this Study Group's Leading Experts (?)
December 2, 2009 | Boston
Seminar: Hot Topics at the Upcoming 51st Annual American Society of Hematology Meeting (Boston)November 28, 2007 | New York
GLGi: Hematology Grand RoundsGLG Webcasts & Teleconferences
Leading Experts in Multiple Myeloma Physicians have not participated in any GLG webcasts.